The expression of PD-L1 (Ventana SP142) in HER2-positive breast cancer and its relationship with clinicopathological characteristics

被引：0
|
作者：
Zhang, Ningning [1 ]
Liu, Yueping [1 ]
机构：
[1] Hebei Med Univ, Hosp 4, Dept Pathol, Shijiazhuang, Hebei, Peoples R China
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
breast cancer; HER2-positive; PD-L1; TILs;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS2-30
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Interobserver Variation of PD-L1 (SP142) Immunohistochemistry Interpretation in Breast Carcinoma
    Hoda, Raza
    Brogi, Edi
    D'Alfonso, Timothy
    Grabenstetter, Anne
    Giri, Dilip
    Hanna, Matthew
    Kuba, M. Gabriela
    Murray, Melissa
    Vallejo, Christina
    Zhang, Hong
    Reis-Filho, Jorge
    Wen, Hannah
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 173 - 175
  • [22] Interobserver Variation of PD-L1 SP142 Immunohistochemistry Interpretation in Breast Carcinoma
    Hoda, Raza S.
    Brogi, Edi
    D'Alfonso, Timothy M.
    Grabenstetter, Anne
    Giri, Dilip
    Hanna, Matthew G.
    Kuba, M. Gabriela
    Murray, Melissa P.
    Vallejo, Christina E.
    Zhang, Hong
    Reis-Filho, Jorge S.
    Wen, Hannah Y.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2021, 145 (09) : 1132 - 1137
  • [23] PD-L1 status by SP142 and sp263 immunohistochemistry in triple-negative breast cancer
    Cordoba, A.
    Mercado, M. D. R.
    Amat, I.
    Beloqui, R.
    Aguiar, B.
    Rodriguez, Y.
    Guerrero-Setas, D.
    VIRCHOWS ARCHIV, 2020, 477 : S44 - S44
  • [24] PD-L1 Expression in Metaplastic Breast Carcinoma (MBC) Using PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical (IHC) Assays
    Grabenstetter, Anne
    Jungbluth, Achim
    Frosina, Denise
    Hoda, Raza
    Weigelt, Britta
    Reis-Filho, Jorge
    Zhang, Hong
    Traina, Tiffany
    Robson, Mark
    Brogi, Edi
    Wen, Hannah
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 159 - 160
  • [25] PD-L1 Expression in Metaplastic Breast Carcinoma (MBC) Using PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical (IHC) Assays
    Grabenstetter, Anne
    Jungbluth, Achim
    Frosina, Denise
    Hoda, Raza
    Weigelt, Britta
    Reis-Filho, Jorge
    Zhang, Hong
    Traina, Tiffany
    Robson, Mark
    Brogi, Edi
    Wen, Hannah
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 159 - 160
  • [26] Implications of PD-L1 expression on the immune microenvironment in HER2-positive gastric cancer
    Chen, Yang
    Jia, Keren
    Chong, Xiaoyi
    Xie, Yi
    Jiang, Lei
    Peng, Haoxin
    Liu, Dan
    Yuan, Jiajia
    Li, Yanyan
    Feng, Xujiao
    Sun, Yu
    Li, Jian
    Zhang, Xiaotian
    Shen, Lin
    MOLECULAR CANCER, 2024, 23 (01)
  • [27] Utilization of Commercial SP142 PD-L1 Testing of Breast Carcinomas at a Large Academic Cancer Center
    Wong, Serena
    Reisenbichler, Emily
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 164 - 165
  • [28] Utilization of Commercial SP142 PD-L1 Testing of Breast Carcinomas at a Large Academic Cancer Center
    Wong, Serena
    Reisenbichler, Emily
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 164 - 165
  • [29] Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer
    Li, Yijin
    Vennapusa, Bharathi
    Chang, Ching-Wei
    Tran, David
    Nakamura, Rin
    Sumiyoshi, Teiko
    Hegde, Priti
    Molinero, Luciana
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2021, 29 (04) : 258 - 264
  • [30] Tumor infiltlating lymphocytes and PD-L1 expression in HER2-positive breast cancer treated with neoadjuvant chemothepary
    Tokunaga, Eriko
    Taguchi, Kenichi
    Nami, Yamashita
    Morita, Masaru
    Ishida, Mayumi
    CANCER SCIENCE, 2018, 109 : 125 - 125
12345